Resultados totales (Incluyendo duplicados): 1743913
Encontrada(s) 174392 página(s)
Encontrada(s) 174392 página(s)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12918
PublicaciónArtículo científico (article). 2020
REAL-TIME LOCALIZATION OF EPILEPTOGENIC FOCI EEG SIGNALS: AN FPGA-BASED IMPLEMENTATION
- Frances-Villora, JV
- Bataller-Mompean, M
- Mjahad, A
- Rosado-Munoz, A
- Martin, AG
- Teruel-Marti, V
- Villanueva, V
- Hampel, KG
- Guerrero-Martinez, JF
The epileptogenic focus is a brain area that may be surgically removed to control of epileptic seizures. Locating it is an essential and crucial step prior to the surgical treatment. However, given the difficulty of determining the localization of this brain region responsible of the initial seizure discharge, many works have proposed machine learning methods for the automatic classification of focal and non-focal electroencephalographic (EEG) signals. These works use automatic classification as an analysis tool for helping neurosurgeons to identify focal areas off-line, out of surgery, during the processing of the huge amount of information collected during several days of patient monitoring. In turn, this paper proposes an automatic classification procedure capable of assisting neurosurgeons online, during the resective epilepsy surgery, to refine the localization of the epileptogenic area to be resected, if they have doubts. This goal requires a real-time implementation with as low a computational cost as possible. For that reason, this work proposes both a feature set and a classifier model that minimizes the computational load while preserving the classification accuracy at 95.5%, a level similar to previous works. In addition, the classification procedure has been implemented on a FPGA device to determine its resource needs and throughput. Thus, it can be concluded that such a device can embed the whole classification process, from accepting raw signals to the delivery of the classification results in a cost-effective Xilinx Spartan-6 FPGA device. This real-time implementation begins providing results after a 5 s latency, and later, can deliver floating-point classification results at 3.5 Hz rate, using overlapped time-windows.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12918
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12918
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12918
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12918
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12918
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12918
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12918
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12918
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12920
PublicaciónArtículo científico (article). 2020
MANAGEMENT OF CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA IN SPAIN: A VIEW FROM THE EXPERTS
- Calleja-Panero, JL
- Andrade, RJ
- Banares, R
- Crespo, J
- Esteban, R
- Jarque, I
- Mingot-Castellano, ME
- Romero-Gomez, M
- Munoz-Penin, R
- Bentley, R
- Shepherd, J
- Gil, A
Background: chronic liver disease (CLD) patients often present thrombocytopenia (TCP) and when severe, it may prevent them from undergoing necessary invasive procedures due to an increased bleeding risk. The lack of scientific evidence makes it impossible to determine key aspects of the current management and associated healthcare burden of these patients in Spain.
Purpose: to gain insight into the current situation of patients with CLD-associated severe TCP undergoing invasive procedures in Spain, based on the experience of clinical experts.
Methods: national Delphi study involving 32 medical experts.
Results: the estimated prevalence of CLD-associated severe TCP is approximately 5,967, with an annual incidence of 1,148 new patients. Patients undergo a median of 1 (0-3) invasive procedures/year. Platelet transfusions (PTs) are the standard option to raise platelet counts and are associated with significant burden. The achievement of target platelet levels (>= 50 x 109/l) after a transfusion is not routinely measured. The lack of effectiveness and short life span of transfused platelets can lead to procedure cancellations and bleeding events, which potentially affect patient outcomes. Adverse events occur in 1-25 % of patients, including mild (febrile and allergic reactions) and severe events (e.g., trans- fusion-related acute lung injury). Between 5-15 % of patients are unfit to receive PTs and approximately 3 % are treated off-label with thrombopoietin receptor agonists.
Conclusions: this study provides a snapshot of the current situation in Spain, highlighting that the current management is poorly standardized and suboptimal in some cases. The results suggest the benefit of developing a consensus document to address some of these shortcomings and to advance in the search for alternatives to PTs.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12920
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12920
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12920
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12920
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12920
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12920
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12920
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12920
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12922
PublicaciónArtículo científico (article). 2020
FLASH GLUCOSE MONITORING REDUCES GLYCEMIC VARIABILITY AND HYPOGLYCEMIA: REAL-WORLD DATA FROM SPAIN
- Gomez-Peralta F
- Dunn T
- Landuyt K
- Xu Y
- Merino-Torres JF
Objective Observations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings.
Research design and methods Deidentified glucose and user scanning data were analyzed and readers were rank ordered into 20 equal sized groups by daily scan frequency. Glucose parameters were calculated for each group: estimated HbA1c, time below range (<70 and <= 54 mg/dL), within range (70-180 mg/dL), and above range (>180 mg/dL). Glycemic variability (GV) metrics were described and data obtained from sensors in Spain and worldwide were compared.
Results Spanish users (n=22 949) collected 37.1 million glucose scans, 250 million automatically recorded glucose readings, and checked glucose values via a mean of 13 scans/day. Estimated HbA1c, time below 70 mg/dL, at or below 54 mg/dL, above 180 mg/dL, and GV metrics were significantly lower in the highest compared with lowest scan rate group (39.6 to 3.9 scans/day). Time-in-range was higher for the highest versus lowest scan rate group at 15.6 vs 11.5 hours/day, respectively. GV metrics correlated positively with time below 70 mg/dL, at or below 54 mg/dL, above 180 mg/dL, and negatively with time-in-range. The relationship between glucose metrics and scan rate was similar in Spain and worldwide. However, time in hypoglycemia in Spain was higher in the groups with lower scan rates.
Conclusions As seen in clinical trials, flash glucose monitoring in real-world settings allows frequent glucose checks. High scan rates are associated with the favorable glycemic markers of increased time-in-range and reduced time in hyperglycemia and hypoglycemia, and GV. The same trends, with unique nuances, are observed in both Spanish and global data.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12922
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12922
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12922
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12922
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12922
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12922
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12922
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12922
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12923
PublicaciónArtículo científico (article). 2020
COST ANALYSIS OF THE FLASH MONITORING SYSTEM (FREESTYLE LIBRE 2) IN ADULTS WITH TYPE 1 DIABETES MELLITUS
- Oyaguez, I
- Merino-Torres, JF
- Brito, M
- Bellido, V
- Cardona-Hernandez, R
- Gomez-Peralta, F
- Morales-Perez, F
Introduction Compare cost of the interstitial liquid glucose flash monitoring (FM) system (FreeStyle Libre 2) versus self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes mellitus (T1DM) in Spain.
Research design and methods A model was developed to estimate, with the perspective of the Spanish health system, the annual costs associated with glucose monitoring and hypoglycemic events management in T1DM population, with multiple insulin daily doses (MDI). According to published evidence, rate of severe hypoglycemia (SHE) of 4.90 episodes per patient-year was applied. Reduction of SHE (58.6%) was modeled associated with FM use. Published rates of hospital care (20.2%) and subsequent admission (16%) were assumed for SHE. The daily consumption of strips and lancets was 9 in patients with SMBG (before and after 4 daily intakes and at bedtime) and 0.5 for FM users (according to IMPACT trial findings). Annual consumption of 26 FM sensors was considered (1 every 14 days). Unit costs (in euro of 2019, excluding VAT) were obtained from literature and national databases. Sensitivity analyses (SA) were carried out to evaluate the model robustness.
Results The total annual cost/patient was euro4437 for SMBG and euro2526 for FM. The use of FM would be associated with an annual savings in the costs of monitoring and managing hypoglycemic events of euro1911 per patient-year. In a hypothetical cohort of 1000 patients with T1DM MDI, FM could avoid in 1 year 4900 SHE, 93 hospitalizations for SHE. In addition, the use of FM would generate total savings of up to euro1 910 000 per year. In the SA with alternative hypoglycemia events rates and use of strips and lancets, and including non-SHE episodes, savings from euro370 000 to euro1 760 000 were observed with FM.
Conclusions The use of the FM system to monitor glucose in adults with T1DM treated with MDI, would reduce hypoglycemic events and would result in cost savings for the health system.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12923
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12923
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12923
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12923
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12923
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12923
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12923
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12923
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12924
PublicaciónArtículo científico (article). 2020
COMPREHENSIVE LONG-TERM FOLLOW UP OF ADULTS WITH ARTERIAL SWITCH OPERATION-EUROPEAN COLLABORATION FOR PROSPECTIVE OUTCOME RESEARCH IN CONGENITAL HEART DISEASE (EPOCH-ASO)-STUDY DESIGN AND PROTOCOLS
- Ruperti-Repilado, FJ
- Ladouceur, M
- Gallego, P
- Dos, L
- Soriano, JR
- Bouma, B
- Gabriel, H
- Schwerzmann, M
- Bouchardy, J
- Tobler, D
- Greutmann, M
Background: Long-term outcomes in adults with prior arterial switch operation (ASO) have not yet been well defined. The aim of this study is to elucidate incidence and predictors of adverse cardiac outcomes in a prospectively followed cohort of adults after their ASO. Methods: The comprehensive long-term follow up of adults with ASO is a project within the European collaboration for prospective outcome research in congenital heart disease (EPOCH). It is designed as a prospective, international multicenter cohort study. Consecutive patients (age >= 16 years) with prior ASO will be included at 11 European tertiary care centers. Participants will be followed according to a standardized protocol following international recommendations, including standardized protocols for imaging and for exercise testing. Results: Main outcome measures are all-cause and cardiac-related mortality, rate of cardiac re-intervention, neo-aortic dissection, myocardial infarction, stroke, infective endocarditis, sustained atrial and ventricular arrhythmias, new-onset or worsening pulmonary hypertension or heart failure. Secondary endpoints are frequency and progression of right ventricular outflow stenosis, neo-aortic root dilatation, neo-aortic valve regurgitation and ventricular dysfunction. The impact of demographic, anatomic (e.g., coronary artery anatomy) and functional variables on the above-mentioned outcomes, as well as quality of life and incidence of pregnancy related complications will also be assessed. Conclusion: The prospective, international, multicenter EPOCH-ASO study will provide a better understanding of adverse outcomes and their predictors in adults after ASO. The results of the EPOCH-ASO study may help to optimize future care of this novel patient cohort in adult cardiology.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12924
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12924
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12924
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12924
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12924
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12924
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12924
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12924
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12925
PublicaciónArtículo científico (article). 2020
CANCER TESTIS ANTIGENS IN MYELODYSPLASTIC SYNDROMES REVISITED: A TARGETED RNA-SEQ APPROACH
- Lopez, AMH
- Chen-Liang TH
- Zurdo M
- Carrillo-Tornel S
- Panadero J
- Salido EJ
- Beltrán V
- Muina, Begona
- Amigo M
- Navarro-Villamor N
- Cifuentes R
- Calabria I
- Antón AI
- Teruel R
- Muro M
- Vicente V
- Jerez A
Cancer-Testis antigens (CTA) are named after the tissues where they are mainly expressed: in germinal and in cancer cells, a process that mimics many gametogenesis features. Mapping accurately the CTA gene expression signature in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) is a prerequisite for downstream immune target-discovery projects. In this study, we take advantage of the use of azacitidine to treat high-risk MDS and CMML to draw the CTAs landscape, before and after treatment, using anad hoctargeted RNA sequencing (RNA-seq) design for this group of low transcript genes. In 19 patients, 196 CTAs were detected at baseline. Azacitidine did not change the number of CTAs expressed, but it significantly increased or decreased expression in nine and five CTAs, respectively.TFDP3andDDX53, emerged as the main candidates for immunotherapeutic targeting, as they showed three main features: i) a significant derepression on day +28 of cycle one in those patients who achieved complete remission with hypomethylating treatment (FC = 6,p= .008; FC = 2.1,p= .008, respectively), ii) similar dynamics at the protein level to what was observed at the RNA layer, and iii) to elicit significant specific cytotoxic immune responses detected by TFDP3 and DDX53 HLA-A*0201 tetramers. Our study addresses the unmet landscape of CTAs expression in MDS and CMML and revealed a previously unrecognizedTFDP3andDDX53reactivation, detectable in plasma and able to elicit a specific immune response after one cycle of azacitidine.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12925
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12925
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12925
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12925
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12925
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12925
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12925
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12925
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12926
PublicaciónArtículo científico (article). 2020
TOCILIZUMAB IN GIANT CELL ARTERITIS: DIFFERENCES BETWEEN THE GIACTA TRIAL AND A MULTICENTRE SERIES OF PATIENTS FROM THE CLINICAL PRACTICE
- Calderon-Goercke, M
- Castaneda, S
- Aldasoro, V
- Villa, I
- Prieto-Pena, D
- Atienza-Mateo, B
- Patino, E
- Moriano, C
- Romero-Yuste, S
- Narvaez, J
- Gomez-Arango, C
- Perez-Pampin, E
- Melero, R
- Becerra-Fernandez, E
- Revenga, M
- Alvarez-Rivas, N
- Galisteo, C
- Sivera, F
- Olive-Marques, A
- del Buergo, MA
- Marena-Rojas, L
- Fernandez-Lopez, C
- Navarro, F
- Raya, E
- Galindez-Agirregoikoa, E
- Arca, B
- Solans-Laque, R
- Conesa, A
- Hidalgo, C
- Vazquez, C
- Roman-Ivorra, JA
- Loricera, J
- Lluch, P
- Manrique-Arija, S
- Vela, P
- De Miguel, E
- Torres-Martin, C
- Nieto, JC
- Ordas-Calvo, C
- Salgado-Perez, E
- Luna-Gomez, C
- de Miera, FJTS
- Fernandez-Llanio, N
- Garcia, A
- Larena, C
- Gonzalez-Vela, C
- Corrales, A
- Varela-Garcia, M
- Aurrecoechea, E
- Dos Santos, R
- Garcia-Manzanares, A
- Ortego, N
- Fernandez, S
- Ortiz-Sanjuan, F
- Corteguera, M
- Hernandez, JL
- Gonzalez-Gay, MA
- Blanco, R
Objective. A potential point of concern among clinicians is whether results derived from the clinical trials can be reasonably applied or generalised to a definable group of patients seen in real world. It can be the case of the GiACTA study that is a phase III randomised controlled trial of tocilizumab (TCZ) in giant cell arteritis (GCA). To address this question, we compared the clinical features and the response to TCZ from the GiACTA trial patients with those from a series of GCA. seen in the daily clinical practice.
Methods. Comparative study of clinical features between patients from the GiACTA trial (overall n=251) and those from a multicentre series of real-world GCA patients undergoing TCZ, therapy (n=134). The diagnosis of GCA in the GiACTA trial was established by the ACR modified criteria whereas in the series of real-world patients it was made by using the ACR criteria, a positive biopsy of temporal artery or the presence of imaging techniques consistent with large-vessel vasculitis in individuals who presented cranial symptoms of GCA. GiACTA trial patients received subcutaneous TCZ (162 mg every 1 or 2 weeks) whereas those from the clinical practice series were treated using standard IV dose (8 mg/kg/month) or subcutaneously (162 mg/week).
Results. Real-life patients undergoing TCZ were older with longer disease duration and higher values of ESR and had received conventional immunosuppressive therapy (mainly methotrexate) more commonly than those included in the GiACTA trial. Despite clinical differences, TCZ, was equally effective in both GiACTA trial and clinical practice patients. However, serious infections were more commonly observed in GCA patients recruited from the clinical practice.
Conclusion. Despite clinical differences with patients recruited in clinical trials, data from real-life patients confirm the efficacy of TCZ, in GCA.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12926
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12926
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12926
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12926
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12926
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12926
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12926
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12926
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12927
PublicaciónArtículo científico (article). 2020
THE GREEK STUDY IN THE EFFECTS OF COLCHICINE IN COVID-19 COMPLICATIONS PREVENTION (GRECCO-19 STUDY): RATIONALE AND STUDY DESIGN
- Deftereos, SG
- Siasos, G
- Giannopoulos, G
- Vrachatis, DA
- Angelidis, C
- Giotaki, SG
- Gargalianos, P
- Giamarellou, H
- Gogos, C
- Daikos, G
- Lazanas, M
- Lagiou, P
- Saroglou, G
- Sipsas, N
- Tsiodras, S
- Chatzigeorgiou, D
- Moussas, N
- Kotanidou, A
- Koulouris, N
- Oikonomou, E
- Kaoukis, A
- Kossyvakis, C
- Raisakis, K
- Fountoulaki, K
- Comis, M
- Tsiachris, D
- Sarri, E
- Theodorakis, A
- Martinez-Dolz, L
- Sanz-Sanchez, J
- Reimers, B
- Stefanini, GG
- Cleman, M
- Filippou, D
- Olympios, CD
- Pyrgakis, VN
- Goudevenos, J
- Hahalis, G
- Kolettis, TM
- Iliodromitis, E
- Tousoulis, D
- Stefanadis, C
Objective: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention.
Methods: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group.
Results: Trial results will be disseminated through peer-reviewed publications and conference presentations.
Conclusion: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (C) 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12927
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12927
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12927
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12927
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12927
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12927
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12927
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12927
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12928
PublicaciónArtículo científico (article). 2020
THE FUTURE OF EXTRACELLULAR VESICLES AS THERANOSTICS - AN ISEV MEETING REPORT
- Soekmadji, C
- Li, B
- Huang, YY
- Wang, HF
- An, TX
- Liu, CC
- Pan, WL
- Chen, J
- Cheung, L
- Falcon-Perez, JM
- Gho, YS
- Holthofer, HB
- Le, MTN
- Marcilla, A
- O'Driscoll, L
- Shekari, F
- Shen, TL
- Torrecilhas, AC
- Yan, XM
- Yang, FQ
- Yin, H
- Xiao, Y
- Zhao, ZZ
- Zou, X
- Wang, Q
- Zheng, L
The utilization of extracellular vesicles (EVs) in clinical theranostics has rapidly advanced in the past decade. In November 2018, the International Society for Extracellular Vesicles (ISEV) held a workshop on "EVs in Clinical Theranostic". Here, we report the conclusions of roundtable discussions on the current advancement in the analysis technologies and we provide some guidelines to researchers in the field to consider the use of EVs in clinical application. The main challenges and the requirements for EV separation and characterization strategies, quality control and clinical investigation were discussed to promote the application of EVs in future clinical studies.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12928
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12928
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12928
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12928
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12928
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12928
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12928
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12928
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12929
PublicaciónArtículo científico (article). 2020
PHARMACEUTICAL CARE TO HOSPITAL OUTPATIENTS DURING THE COVID-19 PANDEMIC. TELEPHARMACY
- Margusino-Framiñán L
- Illarro-Uranga A
- Lorenzo-Lorenzo K
- Monte-Boquet E
- Márquez-Saavedra E
- Fernández-Bargiela N
- Gómez-Gómez D
- Lago-Rivero N
- Poveda-Andrés JL
- Díaz-Acedo R
- Hurtado-Bouza JL
- Sánchez-Gundín J
- Casanova-Martínez C
- Morillo-Verdugo R
Hospital Pharmacy Service (HPS) in Spain have been impacted by the health crisis caused by the COVID-19 pandemic. Thus, the outbreak has forced HPSs to adapt their outpatient consultation services to Telepharmacy to optimize clinical outcomes and reduce the risk of contagion. The purpose of this article is to describe and analyze the experience of HPSs with outpatient Telepharmacy during the COVID-19 pandemic and expose the lessons learned. Measures have been adopted in on-site outpatient pharmacy clinics to prevent exposure of patients and professionals to the virus. These measures are based on national and international recommendations on social distancing and hygiene. With regard to remote outpatient pharmacy services, teleconsultation with drug dispensing has been promoted based on five basic procedures, each with its advantages and limitations: home drug delivery from HPSs, with the advantage of universal access and the limitation of entailing a substantial investment in resources; HPS coordination with primary care pharmacists, which requires no investments but with limited access to some geographic areas; HPS coordination with community pharmacists based on a large network of pharmacies, which requires the patient to go to the pharmacy, without confidentiality being guaranteed for any patient; geolocation and hospital-based medication dispensing, which provides universal access and direct traceability, but entails investment in human resources; and HPS coordination with associations of patients, which does not entail any additional cost but limits the information available on the diseases of society members. Three main lessons have been learned during the pandemic: the satisfactory capacity of HPS to provide outpatient pharmacy consultation services in the setting of a public health crisis; the usefulness of Telepharmacy for the clinical follow-up, healthcare coordination, outpatient counseling, and informed dispensing and delivery of medication (with a high level of satisfaction among patients); and the need to foster -Telepharmacy as a complementary tool through a mixed model of outpatient pharmacy consultation service that incorporates the advantages of each procedure and adapts to the individual needs of each patient in a context of humanized healthcare.
Proyecto: //
DOI: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12929
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12929
HANDLE: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12929
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12929
PMID: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12929
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12929
Ver en: https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12929
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p12929
Advanced search